A new drug for pancreatic cancer has shown significant promise in a landmark study, with reports indicating it nearly doubles survival rates for some patients. The treatment targets a previously "undruggable" aspect of the disease, raising hopes for future treatments. The extent of the improvement varies in reports, with some citing a specific percentage increase in overall survival, while others describe the outcome more generally.